We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 331.00 | 332.00 | 334.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -7.08 | 319.68M |
TIDMOXB
RNS Number : 0914N
Oxford Biomedica PLC
20 September 2023
Director Dealings
Oxford, UK - 20 September 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces the following share purchases by certain Directors and Senior management.
Name of PDMR Number of Number of ordinary T otal number of o rdinary shares now held ordinary shares shares purchased held as a percentage of the Company's share capital Dr. Roch Doliveux 36,130 371,805 0.385% ------------------ ------------------- ---------------------- Dr. Frank Mathias 20,000 20,000 0.020% ------------------ ------------------- ---------------------- Stuart Paynter 4,030 18,687 0.019% ------------------ ------------------- ---------------------- Leone Patterson 5,849 5,849 0.0061% ------------------ ------------------- ---------------------- Catherine Moukheibir 7,226 25,756 0.027% ------------------ ------------------- ---------------------- Stuart Henderson 1,000 10,862 0.011% ------------------ ------------------- ---------------------- Sebastien Ribault* 1,500 - - ------------------ ------------------- ---------------------- Nick Page* 11,678 - - ------------------ ------------------- ---------------------- Matthew Treagus* 3,842 - - ------------------ ------------------- ---------------------- James Miskin* 1,808 - - ------------------ ------------------- ----------------------
*Senior Management
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.
1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Dr. Roch Doliveux ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Non-Executive Chairman ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.7430 36,130 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 36,130 GBP99,104.59 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 10:27 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Dr. Frank Mathias ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Executive Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.7498 20,000 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 20,000 GBP54,996 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 10:26 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Stuart Paynter ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Financial Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.481 4,030 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 4,030 GBP9,998.43 * Aggregated total
----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 08.01 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Leone Patterson ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Non-Executive Director ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.7445 5,849 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 5,849 GBP16,052.58 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 10:28 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name C atherine Moukheibir ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Non-Executive Director ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.7430 7,226 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 7,226 GBP19,820.92 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 10:28 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Stuart Henderson ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Non-Executive Director ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.7497 1,000 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 1,000 GBP2,749.70 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 10:26 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Sebastien Ribault ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Commercial Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound
----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.7497 1,500 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 1,500 GBP4,124.55 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 10:27 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Nick Page ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Operations Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.555 11,678 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 11,678 GBP29,837.29 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 08.08 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name Matthew Treagus ----------------------------- ------------------------------------ 2. Reason for the notification ------------------------------------------------------------------- a) Position/status Chief Information Officer and Chief of Staff ----------------------------- ------------------------------------ b) Initial notification/ Initial Notification amendment ----------------------------- ------------------------------------ 3. Details of the Issuer ------------------------------------------------------------------- a) Name Oxford Biomedica plc ----------------------------- ------------------------------------ b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ------------------------------------ 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------- a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ------------------------------------ b) Nature of the P urchase of shares transaction ----------------------------- ------------------------------------ c) Currency GBP - British pound ----------------------------- ------------------------------------ d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.587949 3,842 ---------- ----------------------------- ------------------------------------ e) Aggregated information * Aggregate volume 3,842 GBP9,942.90 * Aggregated total ----------------------------- ------------------------------------ f) Date of the transaction 2023-09-20; 08.05 ----------------------------- ------------------------------------ g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ------------------------------------ 1. Details of the Person Discharging Managerial Responsibility ("PDMR") a) Name James Miskin ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Technical Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford Biomedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial instrument ISIN: GB00BDFBVT43 Identification code ----------------------------- ----------------------------------- b) Nature of the P urchase of shares transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.74 1,808 ---------- ----------------------------- ----------------------------------- e) Aggregated information * Aggregate volume 1,808 GBP4,953.92 * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2023-09-20; 10:55 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- -----------------------------------
-Ends-
For further information, please contact: Oxford Biomedica plc: Tel: +44 (0)1865 783 000 Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com , www.oxbsolutions.com , and follow us on LinkedIn and YouTube .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDZGZLGGGGFZM
(END) Dow Jones Newswires
September 20, 2023 06:42 ET (10:42 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions